Individualized antithrombotic therapy in high-risk cardiovascular patients

被引：1
|
作者：
Tegtmeyer, Roland [1 ]
Borst, Oliver [1 ]
Gawaz, Meinrad [1 ]
Rath, Dominik [1 ]
机构：
[1] Univ Tubingen, Dept Cardiol & Cardiovasc Med, Tubingen, Germany
来源：
PERSONALIZED MEDICINE | 2018年 / 15卷 / 03期
关键词：
bleeding; coronary artery disease; drug-eluting stent; dual antiplatelet therapy; high risk; myocardial infarction; DUAL-ANTIPLATELET THERAPY; ELUTING STENT IMPLANTATION; RESIDUAL PLATELET-AGGREGATION; CORONARY-ARTERY-DISEASE; ESC FOCUSED UPDATE; MYOCARDIAL-INFARCTION; CLOPIDOGREL; DURATION; THROMBOSIS; MORTALITY;
D O I：
10.2217/pme-2017-0081
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Recent guidelines suggest dual antiplatelet therapy (DAPT) after 'drug-eluting' stent (DES) implantation for 6 months in stable patients and for 12 months in patients after acute coronary syndrome. Serious complications after stent implantation include stent thrombosis, recurrent myocardial infarction, ischemic stroke, cardiovascular death and bleeding. These complications also occur beyond 1 year after coronary intervention. Thus, it is important to consider whether a prolonged DAPT (>12 months after percutaneous coronary intervention) is of benefit to lower thrombo-ischemic events in high-risk patients. This review addresses the results of recent randomized clinical studies (DAPT, ITALIC, OPTIDUAL and PEGASUS) and meta-analyses to support the author's view of which patient collectives might benefit from prolonged DAPT.
引用
收藏
页码：223 / 236
页数：14
相关论文
共 50 条
  • [1] Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events
    Olie, R. H.
    van der Meijden, P. E. J.
    Vries, M. J. A.
    Veenstra, L.
    van 't Hof, A. W. J.
    ten Berg, J. M.
    Henskens, Y. M. C.
    ten Cate, H.
    NETHERLANDS HEART JOURNAL, 2021, 29 (10) : 525 - 535
  • [2] Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
    Sumaya, Wael
    Geisler, Tobias
    Kristensen, Steen D.
    Storey, Robert F.
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (10) : 1583 - 1589
  • [3] Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk
    Espinoza, Clifton
    Mukherjee, Debabrata
    HEART INTERNATIONAL, 2021, 15 (01): : 26 - 36
  • [4] Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
    Capodanno, Davide
    Angiolillo, Dominick J.
    CIRCULATION, 2020, 142 (22) : 2172 - 2188
  • [5] Ticagrelor with or without Aspirin in High-Risk Patients after PCI
    Mehran, R.
    Baber, U.
    Sharma, S. K.
    Cohen, D. J.
    Angiolillo, D. J.
    Briguori, C.
    Cha, J. Y.
    Collier, T.
    Dangas, G.
    Dudek, D.
    Dzavik, V.
    Escaned, J.
    Gil, R.
    Gurbel, P.
    Hamm, C. W.
    Henry, T.
    Huber, K.
    Kastrati, A.
    Kaul, U.
    Kornowski, R.
    Krucoff, M.
    Kunadian, V.
    Marx, S. O.
    Mehta, S. R.
    Moliterno, D.
    Ohman, E. M.
    Oldroyd, K.
    Sardella, G.
    Sartori, S.
    Shlofmitz, R.
    Steg, P. G.
    Weisz, G.
    Witzenbichler, B.
    Han, Y.
    Pocock, S.
    Gibson, C. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 2032 - 2042
  • [6] Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease
    Gusdon, Aaron M.
    Farrokh, Salia
    Grotta, James C.
    SEMINARS IN NEUROLOGY, 2021, 41 (04) : 365 - 387
  • [7] Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention
    Hulshof, Anne-Marije
    Olie, Renske H.
    Vries, Minka J. A.
    Verhezen, Paul W. M.
    van der Meijden, Paola E. J.
    ten Cate, Hugo
    Henskens, Yvonne M. C.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [8] Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials
    Zhu, Houyong
    Xu, Xiaoqun
    Wang, Hanxin
    Chen, Qilan
    Fang, Xiaojiang
    Zheng, Jianwu
    Gao, Beibei
    Tong, Guoxin
    Zhou, Liang
    Chen, Tielong
    Huang, Jinyu
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 9
  • [9] Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions
    Caracciolo, Alessandro
    Mazzone, Paolo
    Laterra, Giulia
    Garcia-Ruiz, Victoria
    Polimeni, Alberto
    Galasso, Salvatore
    Saporito, Francesco
    Carerj, Scipione
    D'Ascenzo, Fabrizio
    Marquis-Gravel, Guillaume
    Giustino, Gennaro
    Costa, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [10] Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study
    Verma, Sanam
    Goodman, Shaun G.
    Tan, Mary K.
    Daneault, Benoit
    Lubelsky, Bruce J.
    Mansour, Samer
    Lam, Andy S.
    Laflamme, David
    Tymchak, Wayne J.
    Welsh, Robert C.
    Rose, Randi C.
    Chetty, Rajendra M.
    Constance, Christian M.
    Cieza, Tomas
    Potter, Brian J.
    Hartleib, Michael C.
    Khan, Razi
    Choi, Richard F.
    Keeble, William
    Dery, Jean-Pierre
    Shukla, Dinkar
    Chua, Grace L.
    Bainey, Kevin R.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021,
12345